Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Official title

A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Overview

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons).

Detailed description

This study is a multicenter, open-label phase 2 trial of Orca-T in adults with acute myeloid leukemia or myelodysplastic syndrome who are not able to receive myeloablative (high intensity) conditioning and are eligible for reduced intensity conditioning (RIC)-alloHCT or non-myeloablative (NMA)-alloHCT with an 8/8 human leukocyte antigen (HLA)-matched related or unrelated donor. The trial is designed to further characterize the safety and tolerability of Orca-T and to perform an initial assessment of the efficacy of Orca-T in participants eligible for RIC-alloHCT or NMA-alloHCT.

Participants will receive Orca-T after the investigator's choice from the RIC and NMA regimens followed by single-agent graft-versus-host disease (GVHD) prophylaxis with tacrolimus.

Prior to the initiation of this study (the SERENE-T Study), a phase 1 study (clinicaltrials.gov number: NCT05088356) was conducted to examine the safety and efficacy of Orca-T in participants receiving RIC-alloHCT. Participants have also been treated previously with Orca-T during an ongoing phase 1b/3 study (NCT05316701 and NCT04013685) in participants receiving a MAC regimen. The results of these studies have prompted Orca Bio to further evaluate Orca-T in participants receiving RIC or NMA.

Interventions

• Biological Orca-T
  An allogeneic stem cell and T-cell immunotherapy biologic

Primary outcome measures

• RIC Cohort: GVHD-free and relapse-free survival (GRFS) [Time frame: Day 0 through day +365 after transplantation]
• NMA Cohort: Incidence of neutrophil engraftment [Time frame: Day 0 through day +28 after transplantation]
• NMA Cohort: Time to neutrophil engraftment [Time frame: Day 0 through day +28 after transplantation]

Secondary outcome measures (12)

• Safety of Orca-T [Time frame: Day 0 through day +100 after transplantation]
• Incidence of serious infections [Time frame: Day 0 through day +365 after transplantation]
• Severity of serious infection [Time frame: Day 0 through day +365 after transplantation]
• Overall survival [Time frame: Day 0 through day +730 after transplantation]
• Non-relapse mortality [Time frame: Day 0 through day +730 after transplantation]
• Relapse-free survival [Time frame: Day 0 through day +730 after transplantation]
• Chronic GVHD-free survival [Time frame: Day 0 through day +730 after transplantation]
• GVHD-free and relapse-free survival (GRFS) [Time frame: Day 0 through day +730 after transplantation]
• Incidence of acute GVHD [Time frame: Day 0 through day +180 after transplantation]
• Severity of acute GVHD [Time frame: Day 0 through day +180 after transplantation]
• Time to onset of acute GVHD [Time frame: Day 0 through day +180 after transplantation]
• Incidence of chronic GVHD [Time frame: Day 0 through day +730 after transplantation]

Eligibility criteria

Inclusion criteria

• Age ≥18 years at the time of enrollment
• Diagnosed with 1 of the following diseases:

• Acute myeloid, or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi), with or without the presence of known minimal residual disease.
• Myelodysplastic syndrome that is indicated for alloHCT per the 2017 International Expert Panel recommendations and/or therapy-related/secondary MDS as defined by the World Health Organization (WHO) classification of myeloid malignancies, with ≤10% blast burden in the bone marrow.
• Planned to undergo 1 of the following preparative regimens as per Investigator discretion:

• RIC cohort: Planned RIC-alloHCT including RIC regimen with TBI/thiotepa/fludarabine
• NMA cohort: Planned NMA-alloHCT including NMA regimen with fludarabine/cyclophosphamide/TBI
• Identified related or unrelated donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1
• Estimated glomerular filtration rate ≥30 mL/minute
• Cardiac ejection fraction at rest ≥40% or shortening fraction of ≥22% by echocardiogram or radionuclide scan (MUGA)
• Diffusing capacity of the lung for carbon monoxide (adjusted for hemoglobin) ≥40%
• Negative serum or urine β-HCG test in persons of childbearing potential
• Alanine transaminase (ALT)/aspartate transaminase (AST) <5 times the upper limit of normal (ULN)
• Total bilirubin <3 × ULN
• Deemed ineligible for a fully myeloablative alloHCT per assessment of the principal investigator

Exclusion criteria

• Prior alloHCT
• Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.
• Planned donor lymphocyte infusion (DLI)
• Planned pharmaceutical in vivo or ex vivo T-cell depletion
• Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor
• Karnofsky performance score <60%
• For RIC cohort only: HCT-Specific Comorbidity Index (HCT-CI) ≥6
• Uncontrolled bacterial, viral, or fungal infection (currently taking antimicrobial therapy and with progression or no clinical improvement) at the time of enrollment
• Seropositive for HIV-1 or -2, HTLV-1 or -2, hepatitis B surface antigen, or HCV antibody unless previously treated with curative therapy and are HCV NAT negative
• Known allergy or hypersensitivity to or intolerance of tacrolimus
• Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
• Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
• Concurrent malignancy within 1 year except nonmelanoma skin cancer that has been curatively resected
• Psychosocial circumstances that preclude the participant being able to go through transplantation or participate responsibly in follow-up care
• Persons who are pregnant or breastfeeding
• Person of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation.
• Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's or medical monitor's judgment, precludes the recipient's safe participation in and completion of the trial or which could affect compliance with the protocol or interpretation of results

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 6 centers

• UCLA Department of Medicine — Los Angeles
• Moffitt Cancer Center — Tampa
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack
• Weill Cornell Medicine - New York Presbyterian Hospital — New York
• Oregon Health and Science University — Portland
• Vanderbilt University, Ingram Cancer Center — Nashville

Identifiers

NCT: NCT07216443 · SERENE-T

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗